14 results on '"White, Julia"'
Search Results
2. Imaging of the axilla before preoperative chemotherapy: Implications for postmastectomy radiation.
- Author
-
Bazan, Jose G. and White, Julia
- Subjects
- *
AXILLA , *MEDICAL imaging systems , *CANCER chemotherapy , *BREAST cancer treatment , *CANCER radiotherapy , *LYMPH node diseases , *BREAST cancer patients - Abstract
Postmastectomy radiation therapy (PMRT) improves breast cancer survival in many women with lymph node-positive disease who undergo surgery followed by adjuvant chemotherapy. The role of PMRT after women receive neoadjuvant chemotherapy (NAC) is less clear. The available data suggest that clinical extent of disease at presentation before NAC, pathologic residual disease (especially pathologically involved lymph nodes) after NAC, and response to NAC are key prognostic factors for locoregional recurrence. Therefore, accurate axillary staging before the initiation of NAC and assessment of response to chemotherapy are critically important. Here, the authors review the literature addressing the radiotherapy management of patients with breast cancer who received NAC and underwent mastectomy with a special focus on the imaging modalities used to assess axillary lymph node status. Cancer 2015;121:1187-1194. © 2014 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Accelerated fractionation with a concurrent boost for early stage breast cancer
- Author
-
Freedman, Gary M., White, Julia R., Arthur, Douglas W., Allen Li, X., and Vicini, Frank A.
- Subjects
- *
CELL fractionation , *CANCER radiotherapy , *BREAST cancer treatment , *RANDOMIZED controlled trials , *CLINICAL trials , *LONGITUDINAL method , *HEALTH outcome assessment , *LUMPECTOMY , *RADIOBIOLOGY - Abstract
Abstract: Hypofractionated radiation refers to treatment with greater than 2Gy per fraction, usually in fewer number and an overall shorter treatment period, compared to conventional radiation fractionation. Randomized prospective trials of hypofractionated whole breast irradiation (WBI) have demonstrated comparable outcomes as conventional fractionation in early stage postlumpectomy radiation in selected groups of patients. These data have changed the traditional radiobiology estimation of the alpha/beta ratio that predicted fractionation sensitivity for breast cancer, suggesting that further increase in dose per fraction is possible for early stage breast cancer without significantly increasing late effects. Many questions remain regarding hypofractionated WBI and span from optimal patient selection to radiation technique including dose planning optimization and the incorporation of a tumor bed boost. A concurrent radiation boost has been studied in a number of single institution studies and has shown to be feasible with acceptable acute and short-term late toxicity. A phase III trial by the Radiation Therapy Oncology Group (RTOG 1005) in North America and other trials in Europe are currently studying in-breast cancer control from hypofractionated WBI with a concurrent tumor bed boost. Results from these current trials could improve the acceptance and broaden the applicability of hypofractionation treatment courses for the treatment of patients with early stage breast cancer. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
4. Is α/β for breast cancer really low?
- Author
-
Qi, X. Sharon, White, Julia, and Li, X. Allen
- Subjects
- *
BREAST cancer , *CLINICAL trials , *CANCER radiotherapy , *PARAMETER estimation , *MATHEMATICAL models , *LUMPECTOMY - Abstract
Abstract: Purpose: Low α/β ratio for breast cancer has drawn a growing interest for exploring hypofractionation for breast irradiation. This work is to confirm the low α/β ratio based on large randomized clinical trials of breast irradiation. Methods and materials: A model based on the generalized linear-quadratic (LQ) model and Poisson statistical model was developed to calculate disease-free survival with consideration of clonogen proliferation during the course of radiation treatment and exponential behavior of survival rate with follow-up time. Outcome data from a series of randomized clinical trials of early-stage breast radiotherapy were fitted to estimate the model parameters. Other clinical outcomes, including treatments with surgery alone or radiotherapy alone were used to validate the model and the estimated parameters. Hypofractionation regimens were proposed based on the newly estimated LQ parameters. Results: Plausible population averaged radiobiologic parameters for breast cancer (95% confidence level) are α/β =2.88 (0.75–5.01) Gy; α =0.08±0.02Gy−1; potential doubling time T d =14.4±7.8day. The analysis of the radiation-alone data suggested an α/β ratio of 3.89±6.25Gy, verifying the low α/β ratio based on the post-lumpectomy irradiation data. The hypofractionation regimens that are equivalent to the conventional regimen of 2.0Gy×25 in 5weeks include 2.26Gy×20, 3.34Gy×10, 4.93Gy×5 or 3.39Gy×10 (BID). Conclusions: The analysis of the available clinical data from multiple institutions support that breast cancer has a low ratio of α/β, encouraging hypofractionated radiotherapy regimens for breast cancer. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. Investigation of Helical Tomotherapy for Partial-Breast Irradiation of Prone-Positioned Patients
- Author
-
Kainz, Kristofer, White, Julia, Herman, Joann, and Li, X. Allen
- Subjects
- *
CANCER tomography , *POSTURE , *RADIOTHERAPY , *CANCER radiotherapy , *BREAST cancer patients , *GUIDELINES , *IRRADIATION - Abstract
Purpose: To investigate whether helical tomotherapy can provide conformal, uniform target-dose coverage for partial-breast irradiation (PBI) of patients positioned prone while achieving organ-at-risk sparing compliant with National Surgical Adjuvant Breast and Bowel Project (NSABP) B-39/Radiation Therapy Oncology Group (RTOG) 0413 guidelines; and to report our initial experience with the delivery of prone-breast PBI treatments using tomotherapy. Methods and Materials: For our pilot study, we generated helical tomotherapy plans upon the images of 10 prone-positioned patients previously treated using conventional techniques. We also generated plans for 4 left-breast prone-positioned PBI patients who were treated using helical tomotherapy, and recalculated the planned sinograms upon the pretreatment megavoltage computed tomographic images. Of the planning target volume (PTV), 95% was prescribed to receive 38.5 Gy, administered twice daily for 5 days. Results: For our pilot study, on average the maximum point dose to the PTV was 41.3 Gy, and 99% or more of the PTV received 90% or more of the prescribed dose. RTOG 0413 dose–volume histogram objectives were fulfilled for all organs at risk except the contralateral breast, which received a maximum point dose as high as 3.2 Gy in 1 case. For the prospective prone-positioned tomotherapy PBI plans, all objectives were met except the contralateral-breast maximum dose, which was 3.7 Gy on average. Dose calculation using the planned sinogram upon the pretreatment megavoltage computed tomographic images indicated consistency with the planned dose distributions. Conclusions: Helical tomotherapy can provide conformal and uniform target-dose coverage simultaneous with adequate sparing of critical structures; in this study only the contralateral breast dose exceeded RTOG 0413 guidelines. Dosimetric results for our 4 prospective patient cases were consistent with those for our 10-case pilot study. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
6. Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer.
- Author
-
Bergom, Carmen, Kelly, Tracy, Bedi, Meena, Saeed, Hina, Prior, Phillip, Rein, Lisa E., Szabo, Aniko, Wilson, J. Frank, Currey, Adam D., and White, Julia
- Subjects
- *
BREAST cancer treatment , *CANCER invasiveness , *CANCER relapse , *CANCER radiotherapy , *BODY mass index , *PROPORTIONAL hazards models , *CANCER risk factors - Abstract
Purpose: Obesity, as measured by the body mass index (BMI), is a risk factor for distant recurrence and decreased survival in breast cancer. We sought to determine whether the BMI correlated with local recurrence and reduced survival in a cohort of predominantly obese women treated with breast conservation therapy.Methods and Materials: From 1998 to 2010, 154 women with early-stage invasive breast cancer and 39 patients with ductal carcinoma in situ underwent prone whole breast irradiation. Cox proportional hazards regression, Kaplan-Meier methods with the log-rank test, and multivariate analysis were used to explore the association of the outcomes with the BMI.Results: The median patient age was 60 years, and the median follow-up duration was 73 months. The median BMI was 33.2 kg/m(2); 91% of the patients were overweight (BMI ≥25 kg/m(2)) and 69% of the patients were clinically obese (BMI ≥30 kg/m(2)). The BMI was significantly associated with the locoregional recurrence-free interval for patients with invasive cancer and ductal carcinoma in situ (hazard ratio [HR], 1.09; P=.047). Also, a trend was seen for increased locoregional recurrence with a higher BMI (P=.09) for patients with invasive disease, which was significant when examining the outcomes with a BMI stratified by the median value of 33.2 kg/m(2) (P=.008). A greater BMI was also significantly associated with decreased distant recurrence-free interval (HR, 1.09; P=.011) and overall survival (HR, 1.09; P=.004); this association remained on multivariate analysis (distant recurrence-free interval, P=.034; overall survival, P=.0007).Conclusions: These data suggest that the BMI might affect the rate of locoregional recurrence in breast cancer patients. A higher BMI predicted a worse distant recurrence-free interval and overall survival. The present investigation adds to the increasing evidence that BMI is an important prognostic factor in early-stage breast cancer treated with breast conservation therapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma—year-5 toxicity and cosmesis.
- Author
-
Rabinovitch, Rachel, Winter, Kathryn, Kuske, Robert, Bolton, John, Arthur, Doug, Scroggins, Troy, Vicini, Frank, McCormick, Beryl, and White, Julia
- Subjects
- *
RADIOISOTOPE brachytherapy , *BREAST cancer treatment , *CANCER radiotherapy , *CLINICAL trials , *HEALTH outcome assessment , *BREAST cancer patients - Abstract
Abstract: Purpose: Radiation Therapy Oncology Group (RTOG) 95-17, a Phase II trial to evaluate multicatheter brachytherapy (mCathBrachy) as the sole method of radiation therapy for Stage I–II breast cancer (BrCa), was the first cooperative group trial in North America to evaluate accelerated partial breast irradiation (APBI) and include patient-reported outcomes (PROs). This report presents the year-5 toxicity and cosmesis data. Methods and Materials: After lumpectomy and axillary dissection for invasive BrCa (tumor size <3cm with zero to three positive lymph nodes), 100 patients (pts), 98 evaluable, were treated (txed) with mCathBrachy from 1997 to 2000 with 34Gy administered twice daily in 10 high-dose-rate fractions or 45Gy in 3.5–6 days as a low-dose-rate implant to 1–2cm beyond the lumpectomy bed. The PROs and physician-reported outcomes of toxicity, cosmesis, and tx satisfaction at year-5 are reported here, defined as data submitted 54–78 months after tx. Results: Grade (G) 1–2 skin toxicity developed in 78% of the pts and G3 in 13% (no G4). The tx effects included skin dimpling/indentation (37%), fibrosis (45%), telangiectasias (45%), skin catheter marks (54%), and symptomatic fat necrosis (15%). Breast asymmetry was reported in 73%. Rates of excellent-to-good cosmesis were similar between PROs (66%) and radiation oncologists (68%). The PROs of tx satisfaction at year-5 was 75%. Conclusions: RTOG 95-17 documents the year-5 skin toxicity and tx effects of mCathBrachy APBI, which are associated with PROs of good-to-excellent cosmesis and high tx satisfaction. This emphasizes the importance of PROs when assessing BrCa tx. National Surgical Adjuvant Breast and Bowel Project B39/RTOG 0413 will allow for definitive comparisons between APBI and whole breast radiation therapy. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
8. Late Toxicity and Patient Self-Assessment of Breast Appearance/Satisfaction on RTOG 0319: A Phase 2 Trial of 3-Dimensional Conformal Radiation Therapy-Accelerated Partial Breast Irradiation Following Lumpectomy for Stages I and II Breast Cancer.
- Author
-
Chafe, Susan, Moughan, Jennifer, McCormick, Beryl, Wong, John, Pass, Helen, Rabinovitch, Rachel, Arthur, Douglas W., Petersen, Ivy, White, Julia, and Vicini, Frank A.
- Subjects
- *
SELF-evaluation , *CANCER radiotherapy , *BREAST cancer treatment , *LUMPECTOMY , *DRUG toxicity , *CLINICAL trials - Abstract
Purpose: Late toxicities and cosmetic analyses of patients treated with accelerated partial breast irradiation (APBI) on RTOG 0319 are presented. Methods and Materials: Patients with stages I to II breast cancer ≤3 cm, negative margins, and ≤3 positive nodes were eligible. Patients received three-dimensional conformal external beam radiation therapy (3D-CRT; 38.5 Gy in 10 fractions twice daily over 5 days). Toxicity and cosmesis were assessed by the patient (P), the radiation oncologist (RO), and the surgical oncologist (SO) at 3, 6, and 12 months from the completion of treatment and then annually. National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, was used to grade toxicity. Results: Fifty-two patients were evaluable. Median follow-up was 5.3 years (range, 1.7-6.4 years). Eighty-two percent of patients rated their cosmesis as good/excellent at 1 year, with rates of 64% at 3 years. At 3 years, 31 patients were satisfied with the treatment, 5 were not satisfied but would choose 3D-CRT again, and none would choose standard radiation therapy. The worst adverse event (AE) per patient reported as definitely, probably, or possibly related to radiation therapy was 36.5% grade 1, 50% grade 2, and 5.8% grade 3 events. Grade 3 AEs were all skin or musculoskeletal-related. Treatment-related factors were evaluated to potentially establish an association with observed toxicity. Surgical bed volume, target volume, the number of beams used, and the use of bolus were not associated with late cosmesis. Conclusions: Most patients enrolled in RTOG 0319 were satisfied with their treatment, and all would choose to have the 3D-CRT APBI again. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Respiration Induced Heart Motion and Indications of Gated Delivery for Left-Sided Breast Irradiation
- Author
-
Qi, X. Sharon, Hu, Angela, Wang, Kai, Newman, Francis, Crosby, Marcus, Hu, Bin, White, Julia, and Li, X. Allen
- Subjects
- *
BREAST cancer , *CANCER radiotherapy , *CANCER tomography , *RESPIRATION , *HEART beat , *MEDICAL statistics - Abstract
Purpose: To investigate respiration-induced heart motion for left-sided breast irradiation using a four-dimensional computed tomography (4DCT) technique and to determine novel indications to assess heart motion and identify breast patients who may benefit from a gated treatment. Methods and Materials: Images of 4DCT acquired during free breathing for 20 left-sided breast cancer patients, who underwent whole breast irradiation with or without regional nodal irradiation, were analyzed retrospectively. Dose distributions were reconstructed in the phases of 0%, 20%, and 50%. The intrafractional heart displacement was measured in three selected transverse CT slices using DLAD (the distance from left ascending aorta to a fixed line [connecting middle point of sternum and the body] drawn on each slice) and maximum heart depth (MHD, the distance of the forefront of the heart to the line). Linear regression analysis was used to correlate these indices with mean heart dose and heart dose volume at different breathing phases. Results: Respiration-induced heart displacement resulted in observable variations in dose delivered to the heart. During a normal free-breathing cycle, heart-induced motion DLAD and MHD changed up to 9 and 11 mm respectively, resulting in up to 38% and 39% increases of mean doses and V25.2 for the heart. MHD and DLAD were positively correlated with mean heart dose and heart dose volume. Respiratory-adapted gated treatment may better spare heart and ipsilateral-lung compared with the conventional non-gated plan in a subset of patients with large DLAD or MHD variations. Conclusion: Proposed indices offer novel assessment of heart displacement based on 4DCT images. MHD and DLAD can be used independently or jointly as selection criteria for respiratory gating procedure before treatment planning. Patients with great intrafractional MHD variations or tumor(s) close to the diaphragm may particularly benefit from the gated treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Interfractional Target Variations for Partial Breast Irradiation
- Author
-
Ahunbay, Ergun E., Robbins, Jared, Christian, Robert, Godley, Andrew, White, Julia, and Li, X. Allen
- Subjects
- *
MAMMOGRAMS , *BREAST cancer , *TREATMENT effectiveness , *DEFORMATIONS (Mechanics) , *TISSUES , *CANCER radiotherapy , *MEDICAL statistics - Abstract
Purpose: In this work, we quantify the interfractional variations in the shape of the clinical target volume (CTV) by analyzing the daily CT data acquired during CT-guided partial breast irradiation (PBI) and compare the effectiveness of various repositioning alignment strategies considered to account for the variations. Methods and Materials: The daily CT data for 13 breast cancer patients treated with PBI in either prone (10 patients) or supine (3 patients) with daily kV CT guidance using CT on Rails (CTVision, Siemens, Malvern, PA) were analyzed. For approximately 25 points on the surface of the CTV, deformation vectors were calculated by means of deformable image registration and verified by visual inspection. These were used to calculate the distances along surface normals (DSN), which directly related to the required margin expansions for each point. The DSN values were determined for seven alignment methods based on volumetric imaging and also two-dimensional projections (portal imaging). Results: The margin expansion necessary to cover 99% of all points for all days was 2.7 mm when utilizing the alignment method based on deformation field data (the best alignment method). The center-of-mass based alignment yielded slightly worse results (a margin of 4.0 mm), and shifts obtained by operator placement (7.9 mm), two-dimensional-based methods (7.0–10.1 mm), and skin marks (13.9 mm) required even larger margin expansions. Target shrinkage was evident for most days by the negative values of DSN. Even with the best alignment, the range of DSN values could be as high as 7 mm, resulting in a large amount of normal tissue irradiation, unless adaptive replanning is employed. Conclusion: The appropriate alignment method is important to minimize the margin requirement to cover the significant interfractional target deformations observed during PBI. The amount of normal tissue unnecessarily irradiated is still not insignificant, and can be minimized if adaptive radiotherapy is applied. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO)
- Author
-
Smith, Benjamin D., Arthur, Douglas W., Buchholz, Thomas A., Haffty, Bruce G., Hahn, Carol A., Hardenbergh, Patricia H., Julian, Thomas B., Marks, Lawrence B., Todor, Dorin A., Vicini, Frank A., Whelan, Timothy J., White, Julia, Wo, Jennifer Y., and Harris, Jay R.
- Subjects
- *
BREAST cancer treatment , *CANCER radiotherapy , *RANDOMIZED controlled trials , *ONCOLOGY - Abstract
Purpose: To present guidance for patients and physicians regarding the use of accelerated partial-breast irradiation (APBI), based on current published evidence complemented by expert opinion. Methods and Materials: A systematic search of the National Library of Medicine''s PubMed database yielded 645 candidate original research articles potentially applicable to APBI. Of these, 4 randomized trials and 38 prospective single-arm studies were identified. A Task Force composed of all authors synthesized the published evidence and, through a series of meetings, reached consensus regarding the recommendations contained herein. Results: The Task Force proposed three patient groups: (1) a “suitable” group, for whom APBI outside of a clinical trial is acceptable, (2) a “cautionary” group, for whom caution and concern should be applied when considering APBI outside of a clinical trial, and (3) an “unsuitable” group, for whom APBI outside of a clinical trial is not generally considered warranted. Patients who choose treatment with APBI should be informed that whole-breast irradiation (WBI) is an established treatment with a much longer track record that has documented long-term effectiveness and safety. Conclusion: Accelerated partial-breast irradiation is a new technology that may ultimately demonstrate long-term effectiveness and safety comparable to that of WBI for selected patients with early breast cancer. This consensus statement is intended to provide guidance regarding the use of APBI outside of a clinical trial and to serve as a framework to promote additional clinical investigations into the optimal role of APBI in the treatment of breast cancer. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
12. ACR Appropriateness Criteria® on Postmastectomy Radiotherapy: Expert Panel on Radiation Oncology—Breast
- Author
-
Taylor, Marie E., Haffty, Bruce G., Rabinovitch, Rachel, Arthur, Douglas W., Halberg, Francine E., Strom, Eric A., White, Julia R., Cobleigh, Melody A., and Edge, Stephen B.
- Subjects
- *
MASTECTOMY complications , *CANCER radiotherapy , *BREAST cancer treatment , *ADJUVANT treatment of cancer , *MEDICAL specialties & specialists , *BREAST cancer surgery - Abstract
This summary focuses on the role of postoperative radiation therapy in patients treated with modified radical mastectomy for invasive breast cancer, particularly in patients receiving systemic therapy. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
13. Variability of Target and Normal Structure Delineation for Breast Cancer Radiotherapy: An RTOG Multi-Institutional and Multiobserver Study
- Author
-
Li, X. Allen, Tai, An, Arthur, Douglas W., Buchholz, Thomas A., Macdonald, Shannon, Marks, Lawrence B., Moran, Jean M., Pierce, Lori J., Rabinovitch, Rachel, Taghian, Alphonse, Vicini, Frank, Woodward, Wendy, and White, Julia R.
- Subjects
- *
BREAST cancer treatment , *CANCER radiotherapy , *RADIATION dosimetry , *DOSE-response relationship (Radiation) , *IMAGE-guided radiation therapy , *STANDARD deviations - Abstract
Purpose: To quantify the multi-institutional and multiobserver variability of target and organ-at-risk (OAR) delineation for breast-cancer radiotherapy (RT) and its dosimetric impact as the first step of a Radiation Therapy Oncology Group effort to establish a breast cancer atlas. Methods and Materials: Nine radiation oncologists specializing in breast RT from eight institutions independently delineated targets (e.g., lumpectomy cavity, boost planning target volume, breast, supraclavicular, axillary and internal mammary nodes, chest wall) and OARs (e.g., heart, lung) on the same CT images of three representative breast cancer patients. Interobserver differences in structure delineation were quantified regarding volume, distance between centers of mass, percent overlap, and average surface distance. Mean, median, and standard deviation for these quantities were calculated for all possible combinations. To assess the impact of these variations on treatment planning, representative dosimetric plans based on observer-specific contours were generated. Results: Variability in contouring the targets and OARs between the institutions and observers was substantial. Structure overlaps were as low as 10%, and volume variations had standard deviations up to 60%. The large variability was related both to differences in opinion regarding target and OAR boundaries and approach to incorporation of setup uncertainty and dosimetric limitations in target delineation. These interobserver differences result in substantial variations in dosimetric planning for breast RT. Conclusions: Differences in target and OAR delineation for breast irradiation between institutions/observers appear to be clinically and dosimetrically significant. A systematic consensus is highly desirable, particularly in the era of intensity-modulated and image-guided RT. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
14. Dose Specification and Quality Assurance of Radiation Therapy Oncology Group Protocol 95-17; a Cooperative Group Study of Iridium-192 Breast Implants as Sole Therapy
- Author
-
Ibbott, Geoffrey S., Hanson, W.F., O'Meara, Elizabeth, Kuske, Robert R., Arthur, Douglas, Rabinovitch, Rachel, White, Julia, Wilenzick, Raymond M., Harris, Irene, and Tailor, Ramesh C.
- Subjects
- *
HEALTH outcome assessment , *BREAST cancer treatment , *RADIATION doses , *CANCER radiotherapy , *RADIOISOTOPE therapy , *BENCHMARKING (Management) , *BREAST tumors , *CLINICAL trials , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RADIOISOTOPE brachytherapy , *RADIOTHERAPY , *RESEARCH , *RESEARCH funding , *JOB qualifications , *PILOT projects , *LUMPECTOMY , *EVALUATION research , *RETROSPECTIVE studies , *EQUIPMENT & supplies ,RESEARCH evaluation - Abstract
Purpose: The Radiation Therapy Oncology Group (RTOG) protocol 95-17 was a Phase I/II trial to evaluate multicatheter brachytherapy as the sole method of adjuvant breast radiotherapy for Stage I/II breast carcinoma after breast-conserving surgery. Low- or high-dose-rate sources were allowed. Dose prescription and treatment evaluation were based on recommendations in the International Commission on Radiation Units and Measurements (ICRU), Report 58 and included the parameters mean central dose (MCD), average peripheral dose, dose homogeneity index (DHI), and the dimensions of the low- and high-dose regions.Methods and Materials: Three levels of quality assurance were implemented: (1) credentialing of institutions was required before entering patients into the study; (2) rapid review of each treatment plan was conducted before treatment; and (3) retrospective review was performed by the Radiological Physics Center in conjunction with the study chairman and RTOG dosimetry staff.Results: Credentialing focused on the accuracy of dose calculation algorithm and compliance with protocol guidelines. Rapid review was designed to identify and correct deviations from the protocol before treatment. The retrospective review involved recalculation of dosimetry parameters and review of dose distributions to evaluate the treatment. Specifying both central and peripheral doses resulted in uniform dose distributions, with a mean dose homogeneity index of 0.83 +/- 0.06.Conclusions: Vigorous quality assurance resulted in a high-quality study with few deviations; only 4 of 100 patients were judged as representing minor variations from protocol, and no patient was judged as representing major deviation. This study should be considered a model for quality assurance of future trials. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.